Evinco Therapeutics and ARMI announce research collaboration to advance a novel NK-EV therapy for Alzheimer’s disease

Collaboration will generate human iPSC-derived brain cell models to investigate the effects of Evinco’s NK-EV platform on neuroinflammation Melbourne, Australia, 21 September 2026 – Evinco Therapeutics Pty Ltd (“Evinco” or “Company”) and the Australian Regenerative Medicine Institute (ARMI) today announced a research collaboration to advance a novel natural killer cell-derived extracellular vesicle (NK-EV) therapy for ... Continued